Program
tenofovir alafenamide
Also written as “E/C/F/TAF”, “TAF” and “B/F/TAF”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · HIV Infections · Hepatitis · Coinfection, led by 7 companies.
Drug pageTenofovir alafenamide: every studyMany companies study it; this page follows only the 61 they lead. All 140 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 499 open or running | phase 4since Oct 23, 2023 | May 13, 2002 | Jun 2027phase 4 · NCT06337032 |
| Johnson & Johnsonits history only | 70 open or running | phase 3since Oct 17, 2014 | Oct 17, 2014 | none ahead |
| Henan Genuine Biotech | 10 open or running | phase 1since May 13, 2025 | May 13, 2025 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Sep 9, 2024 | Sep 9, 2024 | none ahead |
| New Discoveryits history only | 10 open or running | phase 4since Dec 6, 2019 | Dec 6, 2019 | none ahead |
| The Crofoot Research Centerits history only | 10 open or running | phase 4since May 12, 2020 | May 12, 2020 | none ahead |
| Xiamen Amoytop Biotechits history only | 11 open or running | no phasesince Nov 24, 2024 | Nov 24, 2024 | May 31, 2029NCT06707922 |
Also a collaborator on its studies: Merck and F-star Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Henan Genuine Biotech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 13, 2025First study: phase 1 study in HealthyFirst studyNCT07002268 · 15 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
The one study Henan Genuine Biotech leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07002268Healthy · China | 1 | Completed | May 4, 2022 | 15 |
How it is read
Names in the registry
- “E/C/F/TAF”, 17 entries
- “TAF”, 12 entries
- “B/F/TAF”, 10 entries
- “F/TAF”, 8 entries
- “B/F/TAF (TOS)”, 4 entries
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 11 studies
- Hepatitis B, Chronic, 10 studies
- HIV Infections, 7 studies
- Hepatitis, 4 studies
- Coinfection, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.